UTX gene mutation “robs” individuals of natural cancer protection
The UTX gene mutation was found to lead to an increased cancer risk, presenting a potential drug target for preventative therapies.
List view / Grid view
The UTX gene mutation was found to lead to an increased cancer risk, presenting a potential drug target for preventative therapies.
The team will receive $2 million over five years to investigate the CA2 brain region for the development of neurological therapies.
Researchers discovered that cardiovascular damage was caused by reduced microRNA-210 levels in patient cells and mice with type 2 diabetes.
The absence of interleukin-36 receptor antagonist (IL-36Ra) significantly slowed down wound healing in ischemia-reperfusion injuries in mice.
Scientists discover a long noncoding RNA, termed NXTAR, and a small molecule drug that could be used to treat prostate cancer.
Researchers used obese fruit flies to analyse how gene activities affect triacylglyceride levels, unveiling novel drug targets for obesity.
Scientists revealed five proteins that cause blood vessel damage in COVID-19 patients, potentially leading to new drug targets.
Scientists have discovered a novel pathway and enzyme that causes thrombosis in chronic kidney disease (CKD) patients, indicating a new drug target.
Treatment with Viking Therapeutics' dual agonists resulted in mean reductions in body weight of up to 27 percent compared to semaglutide-treated animals.
The small molecule successfully targeted the C9orf72 gene that causes amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
Watch this exclusive interview with Professor Ann Ager, Cardiff University, to discover how CAR T cells could be targeted against solid tumours.
A new computer-aided tool maps allosteric sites in G protein-coupled receptors to search for allosteric drugs to treat a range of diseases.
Scientists have found that Hutchinson-Gilford Progeria Syndrome (HGPS) can be prevented with treatments targeting the cardiovascular system using a novel mouse model.
A new study is the first to identify N-acylethanolamine acid amidase as a new drug target to treat different forms of chronic pain.
German, Norwegian and British scientists have identified molecular targets for therapies that could prevent breast cancer recurrence.